Holzkirchen, Germany, January 14, 2014 – Sandoz announced today it has received Swedish marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device. On January 13, 2014 Sandoz also received marketing authorization for AirFluSal® Forspiro® in Germany.

Sweden has approved the …